Royalty Pharma CEO receives award, gifts LP interests
Pablo G. Legorreta, CEO and Chairman of Royalty Pharma, reported an exempt award of 65,216 Class A Ordinary Shares in settlement of Equity Performance Awards, bringing his direct Class A stake to 1,307,820 shares.
Rhea-AI Filing Summary
Pablo G. Legorreta, CEO and Chairman of Royalty Pharma, reported an exempt award of 65,216 Class A Ordinary Shares in settlement of Equity Performance Awards, bringing his direct Class A stake to 1,307,820 shares. He also made a bona fide gift of 30,000 LP interests in RPI US Partners 2019, LP, representing 300,000 underlying Class A shares; these limited partnership interests may be exchanged into Class A at no additional cost under an exchange agreement. The filing also notes substantial indirect holdings through family entities and trusts, including 9,700,000 Class B and 13,356,742 Class E shares that are exchangeable into Class A, with Class E subject to vesting conditions.
Positive
- None.
Negative
- None.
Insider Trade Summary
30,000 shares gifted
Gift
16 txns
Insider
Legorreta Pablo G.
Role
CEO, Chairman of the Board
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Gift | LP interests in RPI US Partners 2019, LP F2, F3 | 30,000 | $0.00 | $0.00 |
| Grant/Award | Class A Ordinary Shares F1 | 65,216 | $0.00 | $0.00 |
| holding | LP interests in RPI US Partners 2019, LP F3 | -- | -- | -- |
| holding | LP interests in RPI US Partners 2019, LP F3 | -- | -- | -- |
| holding | LP interests in RPI US Partners 2019, LP F3 | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
LP interests in RPI US Partners 2019, LP — 662,701 contracts (Direct);
Class A Ordinary Shares — 1,307,820 shares (Direct);
LP interests in RPI US Partners 2019, LP — 37,074,880 contracts (Indirect, By Legorreta Investments LLC);
LP interests in RPI US Partners 2019, LP — 18,323,630 contracts (Indirect, By Legorreta Investments II LLC);
LP interests in RPI US Partners 2019, LP — 1,470,140 contracts (Indirect, By Spouse);
Class A Ordinary Shares — 1,040,410 shares (Indirect, By Legorreta Children 2002 Trust);
Class A Ordinary Shares — 901,590 shares (Indirect, By GST-Exempt Legorreta 2012 Family Trust);
Class A Ordinary Shares — 600,000 shares (Indirect, By Legorreta 2023 SR Trust);
Class A Ordinary Shares — 460,139 shares (Indirect, By Legorreta Investments LLC);
Class A Ordinary Shares — 292,190 shares (Indirect, By Tata MC 35 Ltd.);
Class A Ordinary Shares — 123,310 shares (Indirect, By IRRA);
Class A Ordinary Shares — 118,500 shares (Indirect, By SEP/IRA);
Class A Ordinary Shares — 41,306 shares (Indirect, By GST-Exempt Legorreta 2020 Family Trust);
Class A Ordinary Shares — 10,000 shares (Indirect, By Son);
Class A Ordinary Shares — 10,000 shares (Indirect, By Daughter);
Class A Ordinary Shares — 6,930 shares (Indirect, By Spouse)
Footnotes (3)
- F1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
- F2. No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.
- F3. Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
Key Figures
Equity award shares: 65,216 Class A Ordinary Shares
Direct Class A holdings after award: 1,307,820 shares
LP interests gifted: 30,000 LP interests
+5 more
8 metrics
Equity award shares
65,216 Class A Ordinary Shares
Grant in settlement of Equity Performance Awards reported on August 5, 2026
Direct Class A holdings after award
1,307,820 shares
Direct Class A Ordinary Shares held by Pablo G. Legorreta following the August 5, 2026 grant
LP interests gifted
30,000 LP interests
Bona fide gift of RPI US Partners 2019, LP interests on August 7, 2026
Underlying Class A for gifted LP interests
300,000 shares
Class A Ordinary Shares underlying the 30,000 LP interests reported as a gift
Direct LP interests after gift
662,701 LP interests
RPI US Partners 2019, LP interests held directly by Legorreta after the gift transaction
Indirect LP interests via Legorreta Investments LLC
37,074,880 LP interests
RPI US Partners 2019, LP interests held indirectly through Legorreta Investments LLC
Family Class B Ordinary Shares
9,700,000 shares
Class B Ordinary Shares held by family vehicles, exchangeable into Class A
Family Class E Ordinary Shares
13,356,742 shares
Class E Ordinary Shares of Holdings held by family vehicles, exchangeable into Class A and subject to vesting
Key Terms
Equity Performance Awards, Rule 16b-3, bona fide gift, Class B Ordinary Shares, +1 more
5 terms
Equity Performance Awards financial
"Reflects the exempt acquisition in connection with the settlement of Equity Performance Awards."
Rule 16b-3 regulatory
"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares."
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
bona fide gift financial
"Transaction code G is described as a bona fide gift of limited partnership interests."
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What gift transaction involving Royalty Pharma (RPRX) did Legorreta report?
Legorreta reported a bona fide gift of 30,000 LP interests in RPI US Partners 2019, LP, representing 300,000 underlying Class A shares. Footnotes state no partnership interests were exchanged, and any future exchanges into Class A would occur for no additional value.
How many Royalty Pharma (RPRX) LP interests does Legorreta hold after the gift?
After the reported gift, Legorreta held 662,701 LP interests in RPI US Partners 2019, LP directly. Additional indirect LP interests are held through family entities, including 37,074,880, 18,323,630 and 1,470,140 interests via Legorreta Investments LLC, Legorreta Investments II LLC and his spouse.
What additional exchangeable securities linked to Royalty Pharma (RPRX) does Legorreta’s family hold?
Family vehicles controlled by Legorreta hold 9,700,000 Class B Ordinary Shares and 13,356,742 Class E Ordinary Shares of Holdings. Each is exchangeable into an equal number of Class A Ordinary Shares, with the Class E shares subject to vesting conditions.
Were these Royalty Pharma (RPRX) transactions made under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked, and no footnote describes a trading plan. The Class A share award is described as exempt under Rule 16b-3, and the LP interest disposition is coded as a bona fide gift.
AI-generated analysis. How Rhea-AI works. Not financial advice.
